Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Xiamen Amoytop Biotech Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	23,818	34,157	29,847	21,296	15,837	11,911
Market Cap Growth	-31.11%	14.44%	40.15%	34.47%	32.96%	-14.13%
Enterprise Value	22,918	33,473	29,272	20,670	15,360	11,446
Last Close Price	58.35	82.75	71.95	50.97	37.71	28.25

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	23.65	33.12	36.06	38.34	55.18	65.73
Forward PE	18.06	25.11	29.30	33.50	28.12	28.12
PS Ratio	6.24	9.24	10.60	10.14	10.37	10.52
PB Ratio	6.56	9.90	11.69	11.35	11.25	10.26
P/TBV Ratio	7.39	11.29	12.53	12.64	12.32	11.74
P/FCF Ratio	61.75	72.18	166.48	95.23	109.98	271.61
P/OCF Ratio	36.25	46.83	69.31	41.59	43.61	50.73
PEG Ratio	1.13	0.93	0.89	-	-	-

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
EV/Sales Ratio	6.00	9.06	10.39	9.84	10.06	10.11
EV/EBITDA Ratio	17.27	25.22	29.29	28.98	38.09	43.97
EV/EBIT Ratio	19.20	27.58	31.46	31.32	42.66	51.64
EV/FCF Ratio	59.42	70.73	163.28	92.42	106.67	260.99

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Debt / Equity Ratio	0.05	0.05	0.00	0.00	0.01	0.02
Debt / EBITDA Ratio	0.14	0.13	0.01	0.01	0.02	0.10
Debt / FCF Ratio	0.48	0.37	0.05	0.04	0.07	0.57
Net Debt / Equity Ratio	-0.25	-0.24	-0.26	-0.35	-0.40	-0.39
Net Debt / EBITDA Ratio	-0.68	-0.63	-0.65	-0.93	-1.39	-1.75
Net Debt / FCF Ratio	-2.33	-1.77	-3.64	-2.96	-3.90	-10.41
Asset Turnover	1.00	1.00	1.04	1.02	0.96	0.87
Inventory Turnover	0.83	0.77	0.82	0.89	1.39	1.18
Quick Ratio	3.92	3.23	3.55	2.80	3.04	4.01
Current Ratio	4.79	3.86	4.34	3.32	3.57	4.71
Return on Equity (ROE)	31.78%	34.36%	37.37%	33.83%	22.35%	16.77%
Return on Assets (ROA)	19.52%	20.43%	21.51%	19.99%	14.09%	10.59%
Return on Invested Capital (ROIC)	39.56%	47.22%	53.10%	55.56%	37.47%	29.64%
Return on Capital Employed (ROCE)	30.70%	33.10%	35.40%	33.80%	24.00%	17.80%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Earnings Yield	4.26%	3.02%	2.77%	2.61%	1.81%	1.52%
FCF Yield	1.62%	1.39%	0.60%	1.05%	0.91%	0.37%
Dividend Yield	1.06%	0.75%	0.86%	0.80%	0.56%	0.35%
Payout Ratio	24.99%	24.52%	20.15%	15.60%	14.17%	11.41%
Buyback Yield / Dilution	-0.64%	-0.38%	-0.56%	-0.29%	-0.39%	-0.18%
Total Shareholder Return	0.43%	0.37%	0.31%	0.51%	0.17%	0.18%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error